Accordingly, da Cunha et al. [50] and Cassis et al. [48] reported that angiotensin converting enzyme (ACE) inhibitors and AT1 receptor antagonist treatments cause anemia, demonstrating hematopoietic side effects of RAS blockers and indicating that Ang II plays an important role in hematopoiesis. The gene discussed is ACE; the disease is anemia (phenotype).